GLP-1 for Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder in which the upper airway repeatedly collapses during sleep, causing brief pauses in breathing followed by arousal. Severity is measured by the apnea-hypopnea index (AHI) — the average number of apnea and hypopnea events per hour of sleep. Mild OSA is defined as an AHI of 5–14 events per hour, moderate as 15–29, and severe as 30 or more. Untreated OSA is associated with fragmented sleep, daytime sleepiness, cognitive impairment, and substantially elevated risk of hypertension, atrial fibrillation, heart attack, stroke, and type 2 diabetes.

Obesity is the single most powerful modifiable risk factor for OSA. Excess adipose tissue — particularly in the neck, tongue, and upper airway structures — reduces the caliber of the airway and impairs the muscle tone that keeps it patent during sleep. Central adiposity also restricts chest-wall movement and diminishes the lung volume that normally tethers the airway open. A global analysis estimated that approximately 936 million adults aged 30–69 have any OSA (AHI ≥5), and roughly 425 million have moderate-to-severe disease [4]. Population surveys over recent decades have shown the prevalence of sleep-disordered breathing rising in step with the obesity epidemic [5].

Positive airway pressure (PAP) therapy — principally continuous positive airway pressure (CPAP) — remains the front-line treatment for moderate-to-severe OSA. However, PAP adherence is poor: a large proportion of patients cannot tolerate or refuse nightly mask wear. For decades, the only alternative strategies were positional therapy, oral appliances, or upper airway surgery, none of which addressed the underlying adiposity-driven mechanism. That changed in 2024, when tirzepatide (Zepbound) became the first drug approved by the FDA specifically for the treatment of moderate-to-severe OSA in adults with obesity.

The hypothesis that a GLP-1 class drug could treat OSA by reducing airway-compressing adiposity was tested in the SCALE Sleep Apnea trial (Blackman et al., 2016 [3]). This randomized, placebo-controlled trial enrolled adults with obesity and moderate-to-severe OSA who were not using CPAP. After 32 weeks, liraglutide 3.0 mg reduced AHI by a mean of 12.2 events per hour compared with 6.1 events per hour in the placebo group — a statistically significant treatment difference of 6.1 events per hour (95% CI −11.0 to −1.2, P=0.015). Body weight fell 5.7% with liraglutide versus 1.6% with placebo. Post-hoc analysis confirmed that the degree of weight loss correlated directly with OSA improvement, supporting an adiposity-mediated mechanism.

The landmark confirmation came from SURMOUNT-OSA, a pair of phase 3 randomized controlled trials reported by Malhotra et al. in the New England Journal of Medicine in October 2024 [1]. Trial 1 enrolled adults with moderate-to-severe OSA and obesity who were NOT using PAP therapy at baseline; Trial 2 enrolled those who were currently using PAP. In both trials, participants were assigned to the maximum tolerated dose of tirzepatide (10 mg or 15 mg weekly) or placebo for 52 weeks. Baseline AHI was 51.5 events per hour in Trial 1 and 49.5 events per hour in Trial 2. In Trial 1, tirzepatide reduced AHI by a mean of 25.3 events per hour versus only 5.3 events per hour with placebo (treatment difference −20.0 events per hour; 95% CI −25.8 to −14.2; P<0.001). In Trial 2, AHI fell 29.3 events per hour with tirzepatide versus 5.5 with placebo (treatment difference −23.8; 95% CI −29.6 to −17.9; P<0.001). These reductions represent approximate decreases of 49% and 59% from baseline in the tirzepatide arms, respectively.

Tirzepatide's benefits in SURMOUNT-OSA extended well beyond the primary AHI endpoint. Significant improvements were also seen in hypoxic burden (a measure of cumulative oxygen deprivation during sleep), patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure [1]. A secondary analysis published in Nature Medicine in 2026 further characterized the cardiometabolic risk improvements associated with SURMOUNT-OSA treatment, documenting reductions in inflammatory markers, blood pressure, and metabolic indices independently meaningful for cardiovascular risk [2]. These multi-domain gains reflect both the direct effect of OSA improvement and the broad metabolic action of the GLP-1/GIP dual agonist.

Based on the SURMOUNT-OSA results, the FDA approved tirzepatide (Zepbound) in December 2024 as the first pharmacological treatment for moderate-to-severe obstructive sleep apnea in adults with obesity — a historic milestone as no drug had previously been approved for OSA as a primary indication. GLP-1 receptor agonists appear to work through multiple pathways: reducing upper-airway fat deposits, lowering systemic inflammation, improving respiratory muscle tone, and reducing the fluid shifts that worsen supine OSA. Whether direct neurological effects on respiratory control contribute to the benefit beyond simple fat loss remains an active area of investigation.

Zepbound (tirzepatide) is FDA-approved for adults with moderate-to-severe OSA (AHI ≥15 events per hour) AND obesity (BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity). This is explicitly an adjunct to a reduced-calorie diet and increased physical activity, and can be used either alone or alongside PAP therapy. The drug is not approved for OSA in the absence of obesity. Diagnosis should be confirmed by polysomnography or a validated home sleep apnea test before initiating treatment.

Patients currently tolerating and adherent to CPAP who want to augment OSA control and reduce cardiometabolic risk may be reasonable candidates, as reflected by Trial 2 of SURMOUNT-OSA. GLP-1 therapy may also be particularly attractive for patients who have failed or refused CPAP, since treating the underlying obesity can reduce the severity of OSA independent of device use. Clinicians should reassess AHI after meaningful weight loss (typically 10–15% body weight) to determine whether PAP settings need adjustment or PAP can be stepped down.

People with mild OSA (AHI 5–14) are outside the currently approved indication for Zepbound, though weight loss in this population often resolves disordered breathing entirely. For patients with class II or III obesity and severe symptomatic OSA, bariatric surgery is an alternative or complementary pathway that produces larger and more durable AHI reductions. The decision should account for the patient's comorbidities, OSA severity, preference regarding invasive versus non-invasive options, and access to surgical expertise.

Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — are the most common adverse events with tirzepatide and occur most frequently during the dose-escalation period. In SURMOUNT-OSA, these were mostly mild to moderate in severity and did not result in high discontinuation rates. Slow titration (the standard schedule reaches maximum tolerated dose over 20+ weeks) and taking the injection with food can reduce GI burden. Patients should be counseled to expect transient symptoms and not interpret them as a signal to stop therapy.

GLP-1 therapy does not replace CPAP in patients with severe or symptomatic OSA who are currently adherent to device therapy. For such patients, the two treatments are complementary: continued PAP addresses symptomatic and acute oxygenation needs while GLP-1 therapy addresses the root cause over months to years. Patients should not be advised to discontinue CPAP in anticipation of AHI improvement until objective measurement confirms adequate control off therapy. Sleep testing should be repeated after achieving a stable lower weight to guide PAP decisions.

Contraindications applicable to all GLP-1 receptor agonists include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis, gallbladder disease, and acute kidney injury are rare but recognized risks. Insurance coverage for Zepbound under an OSA indication may differ from coverage for weight management, and prior authorization requirements vary by payer. Patients should be counseled that OSA can recur with weight regain if the medication is discontinued, underscoring the importance of sustained adherence.